Advances and challenges towards a vaccine against Chagas disease

References

• Rassi A Jr., Rassi A, Marin-Neto JA. Chagas disease. Lancet 2010; 375:1388 - 402; http://dx.doi.org/10.1016/S0140-6736(10)60061-X; PMID: 20399979
   PubMed Web of Science ®Google Scholar
• Pérez-Molina JA, Perez-Ayala A, Moreno S, Fernandez-Gonzalez MC, Zamora J, Lopez-Velez R. Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis. J Antimicrob Chemother 2009; 64:1139 - 47; http://dx.doi.org/10.1093/jac/dkp357; PMID: 19819909
   PubMed Web of Science ®Google Scholar
• Lescure FX, Le Loup G, Freilij H, Develoux M, Paris L, Brutus L, et al. Chagas disease: changes in knowledge and management. Lancet Infect Dis 2010; 10:556 - 70; http://dx.doi.org/10.1016/S1473-3099(10)70098-0; PMID: 20670903
   PubMed Web of Science ®Google Scholar
• Castro JA, de Mecca MM, Bartel LC. Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis). Hum Exp Toxicol 2006; 25:471 - 9; http://dx.doi.org/10.1191/0960327106het653oa; PMID: 16937919
   PubMed Web of Science ®Google Scholar
• Jackson Y, Alirol E, Getaz L, Wolff H, Combescure C, Chappuis F. Tolerance and safety of nifurtimox in patients with chronic chagas disease. Clin Infect Dis 2010; 51:e69 - 75; http://dx.doi.org/10.1086/656917; PMID: 20932171
   PubMed Web of Science ®Google Scholar
• Muratore CA, Batista Sa LA, Chiale PA, Eloy R, Tentori MC, Escudero J, et al. Implantable cardioverter defibrillators and Chagas' disease: results of the ICD Registry Latin America. Europace 2009; 11:164 - 8; http://dx.doi.org/10.1093/europace/eun325; PMID: 19056745
   PubMed Web of Science ®Google Scholar
• Castillo-Riquelme M, Guhl F, Turriago B, Pinto N, Rosas F, Martinez MF, et al. The costs of preventing and treating chagas disease in Colombia. PLoS Negl Trop Dis 2008; 2:e336; http://dx.doi.org/10.1371/journal.pntd.0000336; PMID: 19015725
   PubMedGoogle Scholar
• Dias JC, Silveira AC, Schofield CJ. The impact of Chagas disease control in Latin America: a review. Mem Inst Oswaldo Cruz 2002; 97:603 - 12; http://dx.doi.org/10.1590/S0074-02762002000500002; PMID: 12219120
   PubMed Web of Science ®Google Scholar
• Schofield CJ, Jannin J, Salvatella R. The future of Chagas disease control. Trends Parasitol 2006; 22:583 - 8; http://dx.doi.org/10.1016/j.pt.2006.09.011; PMID: 17049308
   PubMed Web of Science ®Google Scholar
• Lee BY, Bacon KM, Connor DL, Willig AM, Bailey RR. The potential economic value of a Trypanosoma cruzi (Chagas disease) vaccine in Latin America. PLoS Negl Trop Dis 2010; 4:e916; http://dx.doi.org/10.1371/journal.pntd.0000916; PMID: 21179503
   PubMed Web of Science ®Google Scholar
• Montenegro VM, Jimenez M, Pinto Dias JC, Zeledon R. Chagas disease in dogs from endemic areas of Costa Rica. Mem Inst Oswaldo Cruz 2002; 97:491 - 4; http://dx.doi.org/10.1590/S0074-02762002000400006; PMID: 12118277
   PubMed Web of Science ®Google Scholar
• Crisante G, Rojas A, Teixeira MM, Anez N. Infected dogs as a risk factor in the transmission of human Trypanosoma cruzi infection in western Venezuela. Acta Trop 2006; 98:247 - 54; http://dx.doi.org/10.1016/j.actatropica.2006.05.006; PMID: 16797466
   PubMed Web of Science ®Google Scholar
• Estrada-Franco JG, Bhatia V, Diaz-Albiter H, Ochoa-Garcia L, Barbabosa A, Vazquez-Chagoyan JC, et al. Human Trypanosoma cruzi infection and seropositivity in dogs, Mexico. Emerg Infect Dis 2006; 12:624 - 30; PMID: 16704811
   PubMed Web of Science ®Google Scholar
• Gürtler RE, Cecere MC, Lauricella MA, Cardinal MV, Kitron U, Cohen JE. Domestic dogs and cats as sources of Trypanosoma cruzi infection in rural northwestern Argentina. Parasitology 2007; 134:69 - 82; http://dx.doi.org/10.1017/S0031182006001259; PMID: 17032467
   PubMed Web of Science ®Google Scholar
• Reithinger R, Ceballos L, Stariolo R, Davies CR, Gurtler RE. Extinction of experimental Triatoma infestans populations following continuous exposure to dogs wearing deltamethrin-treated collars. Am J Trop Med Hyg 2006; 74:766 - 71; PMID: 16687678
   PubMed Web of Science ®Google Scholar
• Kjos SA, Snowden KF, Craig TM, Lewis B, Ronald N, Olson JK. Distribution and characterization of canine Chagas disease in Texas. Vet Parasitol 2008; 152:249 - 56; http://dx.doi.org/10.1016/j.vetpar.2007.12.021; PMID: 18255233
   PubMed Web of Science ®Google Scholar
• Garg N, Bhatia V. Current status and future prospects for a vaccine against American trypanosomiasis. Expert Rev Vaccines 2005; 4:867 - 80; http://dx.doi.org/10.1586/14760584.4.6.867; PMID: 16372882
   PubMed Web of Science ®Google Scholar
• Cazorla SI, Frank FM, Malchiodi EL. Vaccination approaches against Trypanosoma cruzi infection. Expert Rev Vaccines 2009; 8:921 - 35; http://dx.doi.org/10.1586/erv.09.45; PMID: 19538117
   PubMed Web of Science ®Google Scholar
• Dumonteil E. Vaccine development against Trypanosoma cruzi and Leishmania species in the post-genomic era. Infect Genet Evol 2009; In press http://dx.doi.org/10.1016/j.meegid.2009.02.009; PMID: 19805015
   PubMed Web of Science ®Google Scholar
• Kierszenbaum F. Chagas' disease and the autoimmunity hypothesis. Clin Microbiol Rev 1999; 12:210 - 23; PMID: 10194457
   PubMed Web of Science ®Google Scholar
• Tarleton RL, Zhang L. Chagas Disease Etiology: Autoimmunity or Parasite Persistence?. Parasitol Today 1999; 15:94 - 9; http://dx.doi.org/10.1016/S0169-4758(99)01398-8; PMID: 10322321
   PubMedGoogle Scholar
• Zhang L, Tarleton RL. Parasite persistence correlates with disease severity and localization in chronic Chagas' disease. J Infect Dis 1999; 180:480 - 6; http://dx.doi.org/10.1086/314889; PMID: 10395865
   PubMed Web of Science ®Google Scholar
• DosReis GA. Evasion of immune responses by Trypanosoma cruzi, the etiological agent of Chagas disease. Braz J Med Biol Res 2011; 44:84 - 90; http://dx.doi.org/10.1590/S0100-879X2011007500005; PMID: 21243314
   PubMed Web of Science ®Google Scholar
• Ouaissi A, Da Silva AC, Guevara AG, Borges M, Guilvard E. Trypanosoma cruzi-Induced Host Immune System Dysfunction: A Rationale for Parasite Immunosuppressive Factor(s) Encoding Gene Targeting. J Biomed Biotechnol 2001; 1:11 - 7; http://dx.doi.org/10.1155/S1110724301000055; PMID: 12488621
   PubMedGoogle Scholar
• Alba Soto CD, Solana ME, Poncini CV, Pino-Martinez AM, Tekiel V, Gonzalez-Cappa SM. Dendritic cells devoid of IL-10 induce protective immunity against the protozoan parasite Trypanosoma cruzi.. Vaccine 2010; 28:7407 - 13; http://dx.doi.org/10.1016/j.vaccine.2010.08.105; PMID: 20850535
   PubMed Web of Science ®Google Scholar
• Ouaissi A, Guilvard E, Delneste Y, Caron G, Magistrelli G, Herbault N, et al. The Trypanosoma cruzi Tc52-released protein induces human dendritic cell maturation, signals via Toll-like receptor 2, and confers protection against lethal infection. J Immunol 2002; 168:6366 - 74; PMID: 12055254
   PubMed Web of Science ®Google Scholar
• Alvarez MN, Peluffo G, Piacenza L, Radi R. Intraphagosomal peroxynitrite as a macrophage-derived cytotoxin against internalized Trypanosoma cruzi: consequences for oxidative killing and role of microbial peroxiredoxins in infectivity. J Biol Chem 2011; 286:6627 - 40; http://dx.doi.org/10.1074/jbc.M110.167247; PMID: 21098483
   PubMed Web of Science ®Google Scholar
• Padilla AM, Bustamante JM, Tarleton RL. CD8+ T cells in Trypanosoma cruzi infection. Curr Opin Immunol 2009; 21:385 - 90; http://dx.doi.org/10.1016/j.coi.2009.07.006; PMID: 19646853
   PubMed Web of Science ®Google Scholar
• Parodi C, Padilla AM, Basombrio MA. Protective immunity against Trypanosoma cruzi.. Mem Inst Oswaldo Cruz 2009; 104:Suppl 1 288 - 94; http://dx.doi.org/10.1590/S0074-02762009000900038; PMID: 19753487
   PubMedGoogle Scholar
• de Alencar BC, Persechini PM, Haolla FA, de Oliveira G, Silverio JC, Lannes-Vieira J, et al. Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination. Infect Immun 2009; 77:4383 - 95; http://dx.doi.org/10.1128/IAI.01459-08; PMID: 19651871
   PubMed Web of Science ®Google Scholar
• Sardinha LR, Mosca T, Elias RM, do Nascimento RS, Goncalves LA, Bucci DZ, et al. The liver plays a major role in clearance and destruction of blood trypomastigotes in Trypanosoma cruzi chronically infected mice. PLoS Negl Trop Dis 2010; 4:e578; http://dx.doi.org/10.1371/journal.pntd.0000578; PMID: 20052269
   PubMedGoogle Scholar
• Collins MH, Craft JM, Bustamante JM, Tarleton RL. Oral exposure to Trypanosoma cruzi elicits a systemic CD8+ T cell response and protection against heterotopic challenge.. Infect Immun 2011; 79:3397 - 406; http://dx.doi.org/10.1128/IAI.01080-10; PMID: 21628516
   PubMed Web of Science ®Google Scholar
• Basombrio MA. Trypanosoma cruzi: partial prevention of the natural infection of guinea pigs with a killed parasite vaccine. Exp Parasitol 1990; 71:1 - 8; http://dx.doi.org/10.1016/0014-4894(90)90002-T; PMID: 2113004
   PubMed Web of Science ®Google Scholar
• Basombrío MA, Besuschio S. Trypanosoma cruzi culture used as vaccine to prevent chronic Chagas' disease in mice. Infect Immun 1982; 36:351 - 6; PMID: 6804390
   PubMed Web of Science ®Google Scholar
• Zuñiga C, Palau T, Penin P, Gamallo C, de Diego JA. Protective effect of Trypanosoma rangeli against infections with a highly virulent strain of Trypanosoma cruzi. Trop Med Int Health 1997; 2:482 - 7; http://dx.doi.org/10.1111/j.1365-3156.1997.tb00171.x; PMID: 9217704
   PubMed Web of Science ®Google Scholar
• Basso B, Cervetta L, Moretti E, Carlier Y, Truyens C. Acute Trypanosoma cruzi infection: IL-12, IL-18, TNF, sTNFR and NO in T. rangeli-vaccinated mice. Vaccine 2004; 22:1868 - 72; http://dx.doi.org/10.1016/j.vaccine.2003.11.013; PMID: 15121297
   PubMed Web of Science ®Google Scholar
• Basso B, Moretti E, Fretes R. Vaccination with epimastigotes of different strains of Trypanosoma rangeli protects mice against Trypanosoma cruzi infection. Mem Inst Oswaldo Cruz 2008; 103:370 - 4; http://dx.doi.org/10.1590/S0074-02762008000400010; PMID: 18660992
   PubMed Web of Science ®Google Scholar
• Zuñiga E, Motran C, Montes CL, Diaz FL, Bocco JL, Gruppi A. Trypanosoma cruzi-induced immunosuppression: B cells undergo spontaneous apoptosis and lipopolysaccharide (LPS) arrests their proliferation during acute infection. Clin Exp Immunol 2000; 119:507 - 15; http://dx.doi.org/10.1046/j.1365-2249.2000.01150.x; PMID: 10691924
   PubMed Web of Science ®Google Scholar
• Taibi A, Plumas-Marty B, Guevara-Espinoza A, Schöneck R, Pessoa H, Loyens M, et al. Trypanosoma cruzi: immunity-induced in mice and rats by trypomastigote excretory-secretory antigens and identification of a peptide sequence containing a T cell epitope with protective activity. J Immunol 1993; 151:2676 - 89; PMID: 7689612
   PubMed Web of Science ®Google Scholar
• Wrightsman RA, Miller MJ, Saborio JL, Manning JE. Pure paraflagellar rod protein protects mice against Trypanosoma cruzi infection. Infect Immun 1995; 63:122 - 5; PMID: 7806347
   PubMed Web of Science ®Google Scholar
• Miller MJ, Wrightsman RA, Manning JE. Trypanosoma cruzi: protective immunity in mice immunized with paraflagellar rod proteins is associated with a T-helper type 1 response. Exp Parasitol 1996; 84:156 - 67; http://dx.doi.org/10.1006/expr.1996.0101; PMID: 8932765
   PubMed Web of Science ®Google Scholar
• Frank FM, Petray PB, Cazorla SI, Munoz MC, Corral RS, Malchiodi EL. Use of a purified Trypanosoma cruzi antigen and CpG oligodeoxynucleotides for immunoprotection against a lethal challenge with trypomastigotes. Vaccine 2003; 22:77 - 86; http://dx.doi.org/10.1016/S0264-410X(03)00541-3; PMID: 14604574
   PubMed Web of Science ®Google Scholar
• Crampton A, Vanniasinkam T. Parasite vaccines: the new generation. Infect Genet Evol 2007; 7:664 - 73; http://dx.doi.org/10.1016/j.meegid.2007.06.004; PMID: 17702669
   PubMed Web of Science ®Google Scholar
• Dumonteil E.. DNA vaccines against protozoan parasites: opportunities and challenges. J Biomed Biotechnol 2007:2007; 90520; http://dx.doi.org/10.1155/2007/90520; PMID: 17710244
   PubMed Web of Science ®Google Scholar
• Nogueira RT, Nogueira AR, Pereira MC, Rodrigues MM, Galler R, Bonaldo MC. Biological and immunological characterization of recombinant Yellow Fever 17D viruses expressing a Trypanosoma cruzi Amastigote Surface Protein-2 CD8+ T cell epitope at two distinct regions of the genome. Virol J 2011; 8:127; http://dx.doi.org/10.1186/1743-422X-8-127; PMID: 21418577
   PubMed Web of Science ®Google Scholar
• Takayama E, Ono T, Carnero E, Umemoto S, Yamaguchi Y, Kanayama A, et al. Quantitative and qualitative features of heterologous virus-vector-induced antigen-specific CD8+ T cells against Trypanosoma cruzi infection. Int J Parasitol 2010; 40:1549 - 61; http://dx.doi.org/10.1016/j.ijpara.2010.05.011; PMID: 20620143
   PubMed Web of Science ®Google Scholar
• Miyahira Y, Takashima Y, Kobayashi S, Matsumoto Y, Takeuchi T, Ohyanagi-Hara M, et al. Immune responses against a single CD8+-T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection. Infect Immun 2005; 73:7356 - 65; http://dx.doi.org/10.1128/IAI.73.11.7356-7365.2005; PMID: 16239534
   PubMed Web of Science ®Google Scholar
• Martin DL, Weatherly DB, Laucella SA, Cabinian MA, Crim MT, Sullivan S, et al. CD8+ T-Cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes. PLoS Pathog 2006; 2:e77; http://dx.doi.org/10.1371/journal.ppat.0020077; PMID: 16879036
   PubMed Web of Science ®Google Scholar
• Tzelepis F, de Alencar BC, Penido ML, Claser C, Machado AV, Bruna-Romero O, et al. Infection with Trypanosoma cruzi restricts the repertoire of parasite-specific CD8+ T cells leading to immunodominance. J Immunol 2008; 180:1737 - 48; PMID: 18209071
   PubMed Web of Science ®Google Scholar
• Haolla FA, Claser C, de Alencar BC, Tzelepis F, de Vasconcelos JR, de Oliveira G, et al. Strain-specific protective immunity following vaccination against experimental Trypanosoma cruzi infection. Vaccine 2009; 27:5644 - 53; http://dx.doi.org/10.1016/j.vaccine.2009.07.013; PMID: 19635607
   PubMed Web of Science ®Google Scholar
• Rosenberg CS, Martin DL, Tarleton RL. CD8+ T cells specific for immunodominant trans-sialidase epitopes contribute to control of Trypanosoma cruzi infection but are not required for resistance. J Immunol 2010; 185:560 - 8; http://dx.doi.org/10.4049/jimmunol.1000432; PMID: 20530265
   PubMed Web of Science ®Google Scholar
• Bhatia V, Garg NJ. Previously unrecognized vaccine candidates control Trypanosoma cruzi infection and immunopathology in mice. Clin Vaccine Immunol 2008; 15:1158 - 64; http://dx.doi.org/10.1128/CVI.00144-08; PMID: 18550728
   PubMed Web of Science ®Google Scholar
• Gupta S, Garg NJ. Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice. PLoS Negl Trop Dis 2010; 4:e797; http://dx.doi.org/10.1371/journal.pntd.0000797; PMID: 20706586
   PubMed Web of Science ®Google Scholar
• Tekiel V, Alba-Soto CD, Gonzalez Cappa SM, Postan M, Sanchez DO. Identification of novel vaccine candidates for Chagas' disease by immunization with sequential fractions of a trypomastigote cDNA expression library. Vaccine 2009; 27:1323 - 32; http://dx.doi.org/10.1016/j.vaccine.2008.12.056; PMID: 19162108
   PubMed Web of Science ®Google Scholar
• García EA, Ziliani M, Aguero F, Bernabo G, Sanchez DO, Tekiel V. TcTASV: a novel protein family in Trypanosoma cruzi identified from a subtractive trypomastigote cDNA library. PLoS Negl Trop Dis 2010; 4:e841; http://dx.doi.org/10.1371/journal.pntd.0000841; PMID: 20957201
   PubMedGoogle Scholar
• Ouaissi A, Aguirre T, Plumas Marty B, Piras M, Schoneck R, Gras Masse H, et al. Cloning and sequencing of a 24-kDa Trypanosoma cruzi specific antigen released in association with membrane vesicles and defined by a monoclonal antibody. Biol Cell 1992; 75:11 - 7; http://dx.doi.org/10.1016/0248-4900(92)90119-L; PMID: 1381253
   PubMed Web of Science ®Google Scholar
• Dumonteil E, Escobedo-Ortegon J, Reyes-Rodriguez N, Ramirez-Sierra MJ, Arjona-Torres A. Immunotherapy of Trypanosoma cruzi infection with DNA vaccines in mice. Infect Immun 2004; 72:46 - 53; http://dx.doi.org/10.1128/IAI.72.1.46-53.2004; PMID: 14688079
   PubMed Web of Science ®Google Scholar
• Duthie MS, Kahn M, Zakayan A, White M, Kahn SJ. Parasite-induced chronic inflammation is not exacerbated by immunotherapy before or during Trypanosoma cruzi Infection. Clin Vaccine Immunol 2007; 14:1005 - 12; http://dx.doi.org/10.1128/CVI.00087-07; PMID: 17538117
   PubMed Web of Science ®Google Scholar
• Zapata-Estrella H, Hummel-Newell C, Sanchez-Burgos G, Escobedo-Ortegon J, Ramirez-Sierra MJ, Arjona-Torres A, et al. Control of Trypanosoma cruzi infection and changes in T cell populations induced by a therapeutic DNA vaccine in mice. Immunol Lett 2006; 103:186 - 91; http://dx.doi.org/10.1016/j.imlet.2005.11.015; PMID: 16378645
   PubMed Web of Science ®Google Scholar
• Limon-Flores AY, Cervera-Cetina R, Tzec-Arjona JL, Ek-Macias L, Sanchez-Burgos G, Ramirez-Sierra MJ, et al. Effect of a combination DNA vaccine for the prevention and therapy of Trypanosoma cruzi infection in mice: role of CD4+ and CD8+ T cells. Vaccine 2010; 28:7414 - 9; http://dx.doi.org/10.1016/j.vaccine.2010.08.104; PMID: 20850536
   PubMed Web of Science ®Google Scholar
• Barr SC, Gossett KA, Klei TR. Clinical, clinicopathologic, and parasitologic observations of trypanosomiasis in dogs infected with North American Trypanosoma cruzi isolates. Am J Vet Res 1991; 52:954 - 60; PMID: 1909105
   PubMed Web of Science ®Google Scholar
• Guedes PM, Veloso VM, Tafuri WL, Galvao LM, Carneiro CM, Lana M, et al. The dog as model for chemotherapy of the Chagas' disease. Acta Trop 2002; 84:9 - 17; http://dx.doi.org/10.1016/S0001-706X(02)00139-0; PMID: 12387906
   PubMed Web of Science ®Google Scholar
• Cruz-Chan JV, Bolio-González ME, Colin-Flores R, Ramirez-Sierra MJ, Quijano-Hernandez IA, Dumonteil E. Immunopathology of natural Trypanosoma cruzi infection in dogs. Vet Parasitol 2009; 162:151 - 5; http://dx.doi.org/10.1016/j.vetpar.2009.02.024; PMID: 19324497
   PubMed Web of Science ®Google Scholar
• Basombrio MA, Segura MA, Mora MC, Gomez L. Field trial of vaccination against American trypanosomiasis (Chagas' disease) in dogs. Am J Trop Med Hyg 1993; 49:143 - 51; PMID: 8352387
   PubMed Web of Science ®Google Scholar
• Basso B, Castro I, Introini V, Gil P, Truyens C, Moretti E. Vaccination with Trypanosoma rangeli reduces the infectiousness of dogs experimentally infected with Trypanosoma cruzi.. Vaccine 2007; 25:3855 - 8; http://dx.doi.org/10.1016/j.vaccine.2007.01.114; PMID: 17349724
   PubMed Web of Science ®Google Scholar
• Aparicio-Burgos JE, Ochoa-Garcia L, Zepeda-Escobar JA, Gupta S, Dhiman M, Martinez JS, et al. Testing the Efficacy of a Multi-Component DNA-Prime/DNA-Boost Vaccine against Trypanosoma cruzi Infection in Dogs. PLoS Negl Trop Dis 2011; 5:e1050; http://dx.doi.org/10.1371/journal.pntd.0001050; PMID: 21625470
   PubMed Web of Science ®Google Scholar
• Quijano-Hernandez IA, Bolio-González ME, Rodríguez-Buenfil JC, Ramirez-Sierra MJ, Dumonteil E. Therapeutic DNA vaccine against Trypansomoma cruzi in dogs: a pilot clinical trial. Ann N Y Acad Sci 2008; 1149:343 - 6; http://dx.doi.org/10.1196/annals.1428.098; PMID: 19120245
   PubMed Web of Science ®Google Scholar
• Camargo EP. Perspectives of vaccination in Chagas disease revisited. Mem Inst Oswaldo Cruz 2009; 104:Suppl 1 275 - 80; http://dx.doi.org/10.1590/S0074-02762009000900036; PMID: 19753485
   PubMedGoogle Scholar
• Junqueira C, Caetano B, Bartholomeu DC, Melo MB, Ropert C, Rodrigues MM, et al. The endless race between Trypanosoma cruzi and host immunity: lessons for and beyond Chagas disease. Expert Rev Mol Med 2010; 12:e29; http://dx.doi.org/10.1017/S1462399410001560; PMID: 20840799
   PubMed Web of Science ®Google Scholar
• Engman DM, Leon JS. Pathogenesis of Chagas heart disease: role of autoimmunity. Acta Trop 2002; 81:123 - 32; http://dx.doi.org/10.1016/S0001-706X(01)00202-9; PMID: 11801219
   PubMed Web of Science ®Google Scholar
• Thomas S, Redfern JB, Lidbury BA, Mahalingam S. Antibody-dependent enhancement and vaccine development. Expert Rev Vaccines 2006; 5:409 - 12; http://dx.doi.org/10.1586/14760584.5.4.409; PMID: 16989620
   PubMed Web of Science ®Google Scholar
• Huisman W, Martina BE, Rimmelzwaan GF, Gruters RA, Osterhaus AD. Vaccine-induced enhancement of viral infections. Vaccine 2009; 27:505 - 12; http://dx.doi.org/10.1016/j.vaccine.2008.10.087; PMID: 19022319
   PubMed Web of Science ®Google Scholar
• Guy B, Chanthavanich P, Gimenez S, Sirivichayakul C, Sabchareon A, Begue S, et al. Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine. Vaccine 2004; 22:3563 - 74; http://dx.doi.org/10.1016/j.vaccine.2004.03.042; PMID: 15315835
   PubMed Web of Science ®Google Scholar
• Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 2010; 328:745 - 8; http://dx.doi.org/10.1126/science.1185181; PMID: 20448183
   PubMed Web of Science ®Google Scholar
• Tarleton RL. Parasite persistence in the aetiology of Chagas disease. Int J Parasitol 2001; 31:550 - 4; http://dx.doi.org/10.1016/S0020-7519(01)00158-8; PMID: 11334941
   PubMed Web of Science ®Google Scholar
• Rocha MO, Ribeiro AL, Teixeira MM. Clinical management of chronic chagas cardiomyopathy. Front Biosci 2003; 8:e44 - 54; http://dx.doi.org/10.2741/926; PMID: 12456332
   PubMed Web of Science ®Google Scholar
• Hyland KV, Leon JS, Daniels MD, Giafis N, Woods LM, Bahk TJ, et al. Modulation of autoimmunity by treatment of an infectious disease. Infect Immun 2007; 75:3641 - 50; http://dx.doi.org/10.1128/IAI.00423-07; PMID: 17485457
   PubMed Web of Science ®Google Scholar
• Marin-Neto JA, Cunha-Neto E, Maciel BC, Simoes MV. Pathogenesis of chronic Chagas heart disease. Circulation 2007; 115:1109 - 23; http://dx.doi.org/10.1161/CIRCULATIONAHA.106.624296; PMID: 17339569
   PubMed Web of Science ®Google Scholar
• McKinnon LR, Card CM. HIV vaccine efficacy trials: A brief history, and options for going forward. AIDS Rev 2010; 12:209 - 17; PMID: 21179185
   PubMed Web of Science ®Google Scholar
• Padian NS, McCoy SI, Balkus JE, Wasserheit JN. Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS 2010; 24:621 - 35; http://dx.doi.org/10.1097/QAD.0b013e328337798a; PMID: 20179575
   PubMed Web of Science ®Google Scholar
• Bowalekar S. Adaptive designs in clinical trials. Perspect Clin Res 2011; 2:23 - 7; http://dx.doi.org/10.4103/2229-3485.76286; PMID: 21584178
   PubMedGoogle Scholar
• Ribeiro AL, Rocha MO, Terranova P, Cesarano M, Nunes MD, Lombardi F. T-wave amplitude variability and the risk of death in Chagas Disease. J Cardiovasc Electrophysiol 2011; In press http://dx.doi.org/10.1111/j.1540-8167.2010.02000.x; PMID: 21235679
   PubMed Web of Science ®Google Scholar
• Sarabanda AV, Marin-Neto JA. Predictors of mortality in patients with Chagas' cardiomyopathy and ventricular tachycardia not treated with implantable cardioverter-defibrillators. Pacing Clin Electrophysiol 2011; 34:54 - 62; http://dx.doi.org/10.1111/j.1540-8159.2010.02896.x; PMID: 20946310
   PubMed Web of Science ®Google Scholar
• Barr SC, Warner KL, Kornreic BG, Piscitelli J, Wolfe A, Benet L, et al. A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi.. Antimicrob Agents Chemother 2005; 49:5160 - 1; http://dx.doi.org/10.1128/AAC.49.12.5160-5161.2005; PMID: 16304193
   PubMed Web of Science ®Google Scholar
• Fernandes CD, Tiecher FM, Balbinot MM, Liarte DB, Scholl D, Steindel M, et al. Efficacy of benznidazol treatment for asymptomatic chagasic patients from state of Rio Grande do Sul evaluated during a three years follow-up. Mem Inst Oswaldo Cruz 2009; 104:27 - 32; http://dx.doi.org/10.1590/S0074-02762009000100004; PMID: 19274372
   PubMed Web of Science ®Google Scholar
• Laucella SA, Mazliah DP, Bertocchi G, Alvarez MG, Cooley G, Viotti R, et al. Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy. Clin Infect Dis 2009; 49:1675 - 84; http://dx.doi.org/10.1086/648072; PMID: 19877967
   PubMed Web of Science ®Google Scholar
• Garcia-Alvarez A, Sitges M, Pinazo MJ, Regueiro-Cueva A, Posada E, Poyatos S, et al. Chagas cardiomyopathy: the potential of diastolic dysfunction and brain natriuretic peptide in the early identification of cardiac damage. PLoS Negl Trop Dis 2010; 4:e826; http://dx.doi.org/10.1371/journal.pntd.0000826; PMID: 20877635
   PubMedGoogle Scholar
• Lima-Costa MF, Cesar CC, Peixoto SV, Ribeiro AL. Plasma B-type natriuretic peptide as a predictor of mortality in community-dwelling older adults with Chagas disease: 10-year follow-up of the Bambui Cohort Study of Aging. Am J Epidemiol 2010; 172:190 - 6; http://dx.doi.org/10.1093/aje/kwq106; PMID: 20581155
   PubMed Web of Science ®Google Scholar
• Lorena VM, Lorena IM, Braz SC, Melo AS, Melo MF, Melo MG, et al. Cytokine levels in serious cardiopathy of Chagas disease after in vitro stimulation with recombinant antigens from Trypanosoma cruzi.. Scand J Immunol 2010; 72:529 - 39; http://dx.doi.org/10.1111/j.1365-3083.2010.02462.x; PMID: 21044127
   PubMed Web of Science ®Google Scholar
• Ndao M, Spithill TW, Caffrey R, Li H, Podust VN, Perichon R, et al. Identification of novel diagnostic serum biomarkers for Chagas' disease in asymptomatic subjects by mass spectrometric profiling. J Clin Microbiol 2010; 48:1139 - 49; http://dx.doi.org/10.1128/JCM.02207-09; PMID: 20071547
   PubMed Web of Science ®Google Scholar
• Wang Y, Moreira Mda C, Heringer-Walther S, Ebermann L, Schultheiss HP, Wessel N, et al. Plasma ACE2 activity is an independent prognostic marker in Chagas' disease and equally potent as BNP. J Card Fail 2010; 16:157 - 63; http://dx.doi.org/10.1016/j.cardfail.2009.09.005; PMID: 20142028
   PubMed Web of Science ®Google Scholar
• Fabbro DL, Olivera V, Bizai ML, Denner S, Diez C, Mancipar I, et al. Humoral immune response against P2beta from Trypanosoma cruzi in persons with chronic Chagas disease: its relationship with treatment against parasites and myocardial damage. Am J Trop Med Hyg 2011; 84:575 - 80; http://dx.doi.org/10.4269/ajtmh.2011.10-0261; PMID: 21460013
   PubMed Web of Science ®Google Scholar
• Bottazzi ME, Dumonteil E, Valenzuela JG, Betancourt-Cravioto M, Tapia-Conyer R, Hotez PJ. Bridging the innovation gap for neglected tropical diseases in Mexico: capacity building for the development of a new generation of antipoverty vaccines. Bol Med Hosp Infant Mex 2011; 68:130 - 8
   Google Scholar
• Araújo AF, de Alencar BC, Vasconcelos JR, Hiyane MI, Marinho CR, Penido ML, et al. CD8+-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2. Infect Immun 2005; 73:6017 - 25; http://dx.doi.org/10.1128/IAI.73.9.6017-6025.2005; PMID: 16113322
   PubMed Web of Science ®Google Scholar
• de Alencar BC, Araujo AF, Penido ML, Gazzinelli RT, Rodrigues MM. Cross-priming of long lived protective CD8+ T cells against Trypanosoma cruzi infection: importance of a TLR9 agonist and CD4+ T cells. Vaccine 2007; 25:6018 - 27; http://dx.doi.org/10.1016/j.vaccine.2007.05.022; PMID: 17629597
   PubMed Web of Science ®Google Scholar
• Hoft DF, Eickhoff CS, Giddings OK, Vasconcelos JR, Rodrigues MM. Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic Trypanosoma cruzi immunity involving CD8+ CTL and B cell-mediated cross-priming. J Immunol 2007; 179:6889 - 900; PMID: 17982080
   PubMed Web of Science ®Google Scholar
• Giddings OK, Eickhoff CS, Sullivan NL, Hoft DF. Intranasal vaccinations with the trans-sialidase antigen plus CpG Adjuvant induce mucosal immunity protective against conjunctival Trypanosoma cruzi challenges. Infect Immun 2010; 78:1333 - 8; http://dx.doi.org/10.1128/IAI.00278-09; PMID: 20048046
   PubMed Web of Science ®Google Scholar
• Cazorla SI, Frank FM, Becker PD, Arnaiz M, Mirkin GA, Corral RS, et al. Redirection of the immune response to the functional catalytic domain of the cystein proteinase cruzipain improves protective immunity against Trypanosoma cruzi infection. J Infect Dis 2010; 202:136 - 44; http://dx.doi.org/10.1086/652872; PMID: 20497050
   PubMed Web of Science ®Google Scholar
• Eickhoff CS, Giddings OK, Yoshida N, Hoft DF. Immune responses to gp82 provide protection against mucosal Trypanosoma cruzi infection. Mem Inst Oswaldo Cruz 2010; 105:687 - 91; http://dx.doi.org/10.1590/S0074-02762010000500015; PMID: 20835618
   PubMed Web of Science ®Google Scholar
• Machado AV, Cardoso JE, Claser C, Rodrigues MM, Gazzinelli RT, Bruna-Romero O. Long-term protective immunity induced against Trypanosoma cruzi infection after vaccination with recombinant adenoviruses encoding amastigote surface protein-2 and trans-sialidase. Hum Gene Ther 2006; 17:898 - 908; http://dx.doi.org/10.1089/hum.2006.17.898; PMID: 16972758
   PubMed Web of Science ®Google Scholar
• Duan X, Yonemitsu Y, Chou B, Yoshida K, Tanaka S, Hasegawa M, et al. Efficient protective immunity against Trypanosoma cruzi infection after nasal vaccination with recombinant Sendai virus vector expressing amastigote surface protein-2. Vaccine 2009; 27:6154 - 9; http://dx.doi.org/10.1016/j.vaccine.2009.08.026; PMID: 19712768
   PubMed Web of Science ®Google Scholar
• Garg N, Tarleton RL. Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection. Infect Immun 2002; 70:5547 - 55; http://dx.doi.org/10.1128/IAI.70.10.5547-5555.2002; PMID: 12228281
   PubMed Web of Science ®Google Scholar
• Chou B, Hiromatsu K, Hisaeda H, Duan X, Imai T, Murata S, et al. Genetic immunization based on the ubiquitin-fusion degradation pathway against Trypanosoma cruzi.. Biochem Biophys Res Commun 2010; 392:277 - 82; http://dx.doi.org/10.1016/j.bbrc.2009.12.166; PMID: 20059980
   PubMed Web of Science ®Google Scholar
• Eickhoff CS, Vasconcelos JR, Sullivan NL, Blazevic A, Bruna-Romero O, Rodrigues MM, et al. Co-administration of a plasmid DNA encoding IL-15 improves long-term protection of a genetic vaccine against Trypanosoma cruzi.. PLoS Negl Trop Dis 2011; 5:e983; http://dx.doi.org/10.1371/journal.pntd.0000983; PMID: 21408124
   PubMed Web of Science ®Google Scholar
• Rigato PO, de Alencar BC, de Vasconcelos JR, Dominguez MR, Araujo AF, Machado AV, et al. Heterologous plasmid DNA prime-recombinant human adenovirus 5 boost vaccination generates a stable pool of protective long-lived CD8(+) T effector memory cells specific for a human parasite, Trypanosoma cruzi.. Infect Immun 2011; 79:2120 - 30; http://dx.doi.org/10.1128/IAI.01190-10; PMID: 21357719
   PubMed Web of Science ®Google Scholar
• Sanchez-Burgos G, Mezquita-Vega G, Escobedo-Ortegon J, Ramirez-Sierra MJ, Arjona-Torres A, Rodrigues MM, et al. Comparative efficacy of DNA vaccines encoding various Trypanosoma cruzi antigens. FEMS Microbiol Med Immunol 2007; 50:333 - 41; http://dx.doi.org/10.1111/j.1574-695X.2007.00251.x
   PubMed Web of Science ®Google Scholar